IP Library Granted Patent US 11,324,737
Granted Patent B1
US 11,324,737 · App. 17/330,162 · Granted May 10, 2022

Modulating expression level of a gene encoding a heat shock protein by treating a human subject with a nitroxide

Inventor: Louis Habash (Irvine, CA)
A61K31/45A61P9/10A61P25/28A61P31/00A61P35/00A61P39/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,324,737
App. No.
17/330,162
Granted
May 10, 2022
Kind
B1
Abstract

Some embodiments disclosed herein include a method for decreasing an expression level of a gene. The methods can include identifying a human subject having an increased expression level of HSP90; and administering to the human subject an effective amount of a nitroxide antioxidant, whereby expression level of the gene is decreased.

Claims (13)

1. A method of decreasing expression level of one or more genes encoding HSP90, the method comprising:

administering an effective amount of a nitroxide antioxidant to a subject having or at risk of an increased expression level of one or more genes expressing HSP90, wherein the expression level of the one or more genes encoding HSP90 is decreased.

2. The method of claim 1 , wherein the subject has a disease associated with increased expression levels of one or more genes encoding HSP90.

3. The method of claim 1 , wherein the subject has a vascular disease.

4. The method of claim 1 , wherein decreasing the expression level of the one or more genes treats a disease caused by increased heat shock protein activity.

5. The method of claim 1 , wherein the subject has or is at risk of developing cancer.

6. The method of claim 1 , wherein the subject has a disease associated with respiratory inflammation.

7. The method of claim 1 , wherein the subject has a neurodegenerative disease.

8. The method of claim 1 , wherein the decreased expression level of one or more genes encoding a heat shock protein reduces a rate of senescence.

9. The method of claim 1 , wherein the subject has atherosclerosis.

10. The method of claim 1 , wherein the subject has elevated expression levels of HIF1a, and wherein the administration of the nitroxide antioxidant destabilizes HIF1a.

11. The method of claim 1 , wherein the nitroxide antioxidant is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl.

12. The method of claim 1 , wherein the subject has one or more tumors, and wherein the decreased expression of HSP90 reduces the size of the one or more tumors.

Cited By (1)
US 12,208,089